We are live on ! Find out more
BSPM

Biostar Pharmaceuticals, Inc.
BSPM

Delisted

BSPM was delisted on the 18th of September, 2018.

Back to rankings

13 hedge funds and large institutions have $1.04M invested in Biostar Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

30% more funds holding

Funds holding: 10 → 13 (+3)

25% less capital invested

Capital invested by funds: $1.39M → $1.04M (-$352K)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
13
Holders Change
+3
Holders Change %
+30%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EGA
Eagle Global Advisors
Texas
+$47.7K
2
Jane Street
Jane Street
New York
+$38.1K
3
Renaissance Technologies
Renaissance Technologies
New York
+$35.7K
4
Citadel Advisors
Citadel Advisors
Florida
+$23.8K
5
Citigroup
Citigroup
New York
+$353

Top Sellers

Rank Fund Capital Flow
1
N
Natixis
France
-$54K
2
SIM
Spark Investment Management
New York
-$28.1K
3
TRCT
Tower Research Capital (TRC)
New York
-$20.1K
4
U
UBS
Switzerland
-$6.31K
5
Morgan Stanley
Morgan Stanley
New York
-$5.29K

BSPM Hedge Fund Activity: Q2 2014 in Review

13 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q2 2014, worth a combined $1.04M — down 25% from $1.39M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BSPM positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 4 trimmed.

The largest buyer was Eagle Global Advisors, opening a new position worth an estimated $47.7K. The largest seller was Natixis, exiting entirely with an estimated $54K sold.

  • 13 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q2 2014, up from 10 in Q1 2014.
  • Funds reported $1.04M of Biostar Pharmaceuticals, Inc. stock for Q2 2014, down 25% quarter-over-quarter.
  • 4 funds opened new Biostar Pharmaceuticals, Inc. positions in Q2 2014 and 1 closed out, a net change of +3 holders.
  • The largest Biostar Pharmaceuticals, Inc. buyer in Q2 2014 was Eagle Global Advisors, an estimated $47.7K added.
  • The largest Biostar Pharmaceuticals, Inc. seller in Q2 2014 was Natixis, an estimated $54K sold.

Based on aggregated 13F filings for Q2 2014.